ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2299건의 자료가 검색되었습니다.
No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
---|---|---|---|---|---|---|---|---|---|---|---|
2285 | Completed | A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19 | COVID-19 | Drug: Convalesscent Plasma | Phase 2 | Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen | OTHER | 106 | All | 18 Years ~ 75 Years | University Hospital Ulm, Ulm, Baden-Wurttmberg, Germany University Hopsital Frankfurt, Frankfurt, Hessia, Germany Saarland University Hospital, Homburg, Saarland, Germany University Hospital Berlin, Charite, Berlin, Germany Universitiy Hospital Dresden, Dresden, Germany University Dusseldorf, Dusseldorf, Germany University Hospital Freiburg, Freiburg, Germany University Hospital Gießen, Gießen, Germany University Hopsital Greifswald, Greifswald, Germany Stadtisches Klinikum Karslruhe, Karlsruhe, Germany Universtity Hospital Schleswig-Holstein, Kiel, Germany Universtity Hospital Schleswig-Holstein, Lubeck, Germany University Hospital Mannheim, Mannheim, Germany University Hospital Marburg, Marburg, Germany Klinikum Stuttgart, Stuttgart, Germany University Hospital Tubingen, Tubingen, Germany |
2284 | Unknown status | A Clinical Trial of Gargling Agents in Reducing Intraoral Viral Load Among COVID-19 Patients | Covid-19 | Drug: Gargle/Mouthwash | Not Applicable | Aga Khan University, University of Karachi | OTHER | 50 | All | 18 Years ~ 65 Years | |
2283 | Unknown status | A Clinical Trial of Immuno-bridging Between Different Manufacture Scales of Recombinant COVID-19 Vaccine (Sf9 Cell) | SARS-CoV-2 Pneumonia | Biological: Recombinant COVID-19 vaccine (Sf9 cell) | Not Applicable | WestVac Biopharma Co., Ltd. | INDUSTRY | 892 | All | 18 Years ~ 59 Years | Jiangsu Provincial Center for Disease Control and Prevention, Huai'an, Jiangsu, China |
2282 | Completed | A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients | COVID-19 | Drug: Suspension of heat killed (autoclaved) Mycobacterium w Drug: Placebo |
Not Applicable | Cadila Pharnmaceuticals, Council of Scientific and Industrial Research, India | INDUSTRY | 40 | All | 18 Years | All India Institute of Medical Science, Raipur, Raipur, Chhattisgarh, India All India Institute of Medical Sciences, Bhopal, Bhopal, Madhya Pradesh, India Postgraduate Institute of Medical Education and Research, Chandigarh, India All lndia Institute of Medical Science, Delhi, Delhi, India |
2281 | Not yet recruiting | A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination | COVID-19 | Biological: Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C) Biological: Recombinant COVID-19 vaccine(Sf9 Cell) (WSK-V101) |
Phase 2 | WestVac Biopharma Co., Ltd. | INDUSTRY | 3100 | All | 18 Years | |
2280 | Completed | A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19 | COVID-19 | Drug: Levilimab Drug: Placebo |
Phase 3 | Biocad | INDUSTRY | 206 | All | 18 Years | State Budgetary Healthcare Institution Kaluga region "Kaluga Regional Clinical Hospital", Kaluga, Russian Federation State Budget Institution of the Republic of Dagestan "Republican Clinical Hospital", Macha?kala, Russian Federation A.N. Bakulev National Medical Research Center of Cardiovascular Surgery, Moscow, Russian Federation City Clinical Hospital No. 40 of the Department of Health of the city of Moscow, Moscow, Russian Federation City Clinical Hospital No.52, Moscow, Russian Federation City Clinical Hospital № 15 named. O.M. Filatov, Moscow, Russian Federation City Clinical Hospital №1 named after N.I. Pirogov, Moscow City Health Department, Moscow, Russian Federation Federal State Budgetary Institution "Central Clinical Hospital with Clinic", Office of the President of the Russian Federation, Moscow, Russian Federation I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation Pirogov Russian National Research Medical University, Moscow, Russian Federation Railway clinical hospital named after N.A. Semashko, Moscow, Russian Federation Almazov National Medical Research Centre, Saint Petersburg, Russian Federation Clinical Infectious Disease Hospital named after S.P. Botkin, Saint Petersburg, Russian Federation North-western State Medical University named after I.I.Mechnikov, Saint Petersburg, Russian Federation Federal State Budgetary Educational Institution of Higher Education "Bashkir State Medical University" of the Ministry of Healthcare of the Russian Federation, Ufa, Russian Federation Federal State Budgetary Educational Institution of Higher Education "North Ossetian State Medical Academy" of the Ministry of Health of the Russian Federation (FSBEI HE SOGMA of the Ministry of Health of Russia), Vladikavkaz, Russian Federation |
2279 | Recruiting | A Clinical Trial on Booster Immunization of Two COVID-19 Vaccines Constructed From Different Technical Routes | COVID-19 | Biological: Prototype and Omicron BA.4/5 Bivalent Recombinant COVID-19 Vaccine(Adenovirus Type 5 Vector) For Inhalation Biological: Bivalent COVID-19 mRNA Vaccine Biological: Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) For Inhalation |
Not Applicable | Zhongnan Hospital, Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China | OTHER | 450 | All | 18 Years | Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China |